Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period

American Journal of Transplantation

Volumn 8, Issue 9, 2008, Pages 1871-1877

  Luan, F L ^a,d   Zhang, H ^b   Schaubel, D E ^b   Miles, C D ^a,c   Cibrik, D ^a   Norman, S ^a   Ojo, A O ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d NONE   (United States)

Author keywords

Calcineurin inhibitor agents; Kidney transplantation; New onset diabetes mellitus

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; GLUCOSE METABOLISM; HUMAN; INCIDENCE; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

BLOOD GLUCOSE; COHORT STUDIES; CYCLOSPORINE; DIABETES MELLITUS; FASTING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; GRAFT SURVIVAL; GUIDELINES AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 49649104768     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02328.x     Document Type: Article

References (26)

1. Krentz AJ, Wheeler DC. New-onset diabetes after transplantation: A threat to graft and patient survival. Lancet 2005 365 : 640 642.
2. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002 62 : 1440 1446.
3. Hjelmesaeth J, Hartmann A, Leivestad T et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006 69 : 588 595.
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 3 : 178 185.
5. Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 1998 65 : 380 384.
6. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985 5 : 196 202.
7. Cosio FG, Kudva Y, Van Der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005 67 : 2415 2421.
8. Wilkinson A, Davidson J, Dotta F et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005 19 : 291 298.
9. American Diabetes A. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2007 30 : S42 S47.
10. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004 4 : 583 595.
11. Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006 81 : 335 341.
12. van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005 79 : 1465 1469.
13. Marcen R, Morales JM, del Castillo D et al. Posttransplant diabetes mellitus in renal allograft recipients: A prospective multicenter study at 2 years. Transplant Proc 2006 38 : 3530 3532.
14. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007 7 : 1506 1514.
15. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. N Engl J Med 2007 357 : 2562 2575.
16. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004 4 : 937 945.
17. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001 12 : 368 373.
18. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004 77 : 1199 1202.
19. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997 63 : 977 983.
20. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997 64 : 436 443.
21. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000 69 : 834 841.
22. Chamienia A, Biedunkiewicz B, Krol E, Debska-Slizien A, Rutkowski B. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc 2006 38 : 81 85.
23. Marcen R, Chahin J, Alarcon A, Bravo J. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: A prospective study. Transplant Proc 2006 38 : 2427 2430.
24. Meier M, Nitschke M, Weidtmann B et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: A randomized controlled trial. Transplantation 2006 81 : 1035 1040.
25. Backman LA. Post-transplant diabetes mellitus: The last 10 years with tacrolimus. Nephrol Dial Transplant 2004 19 (Suppl 6 vi13 vi16.
26. Bolin PJS, Mulloy F, Gao L, Henning J, Bartucci A, Holman M, First J Jr., MR. Optimizing Tacrolimus Therapy in Maintenance Renal Allograft: 12 Month Results. Am J Transplant 2007 7 (S2 207.